BMI View: We continue viewing Iran as one of the less attractive regional markets. Imposition of more stringent international sanctions, rampant inflation, and the loss of confidence in the Iranian rial weigh heavily on consumption and investment patterns, and also on government revenues and ...

more

BMI View: While Ghana’s business environment is superior to that of almost all of its neighbours in West and Central Africa, its domestic market is relatively small and it still struggles to attract investment from major multinational drugmakers. BMI believes Ghana is a perfect market in ...

more

BMI View: Regionally speaking, Oman represents a moderately attractive market. While its positives include well-developed healthcare and an improved intellectual property (IP) environment, Oman is a small market, limited by a modest population of under 3mn. Nevertheless, the traditionally ...

more

Oman’s pharmaceutical market is modest by both regional and global standards. At consumer prices, the market was valued at OMR133mn (US$345mn) in 2010. However, the traditional preference for patented drugs, which account for over 80% of total pharmaceutical spending, do provide a commercial ...

more

BMI View: Uzbekistan is the most populous country in Central Asia and has a rapidly growing economy and a commitment to spend around US$1bn on its pharmaceutical industry over the next five years – including projects with foreign investors. Investment in the country represents a huge ...

more